SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES

NIH RePORTER · NIH · N43 · $599,977 · view on reporter.nih.gov ↗

Abstract

This contract is part of the NIAID Adjuvant Development program, which supports the preclinical development of novel vaccine adjuvant candidates. The goal of this contract is to support the further development of the ASP-1 adjuvant within the context of a vaccine to protect against influenzas.

Key facts

NIH application ID: 10281989
Project number: 75N93020C00041-0-9999-1
Recipient: CELDARA MEDICAL, LLC
Principal Investigator: PAUL GUYRE
Activity code: N43
Funding institute: NIH
Fiscal year: 2020
Award amount: $599,977
Award type: —
Project period: 2020-09-01 → 2022-08-31